Health Care

Gilead’s Phase 3 ARTISTRY results show a single‑tablet bictegravir/lenacapavir combo keeping HIV suppressed, positioning it for long‑acting therapy, market access, and strategic growth.

Illumina’s new CLIA‑certified lab will deliver rapid, whole‑genome sequencing to FIPRD, boosting diagnostic speed, patient access, and the company’s clinical revenue stream amid a volatile market.

HCA Healthcare’s March 2024 conference plans, new executive bonus program tying EBITDA and quality metrics, and Asheville remediation show a strategy to boost financial health, clinical excellence and investor confidence.

Boston Scientific’s recent SEC filings reveal a focus on governance and a possible business combination, hinting at strategic growth in the medical device market.

Explore how CVS Health’s $5.2 billion Oak Street acquisition and PBM lawsuit impact its debt, margins, and share price volatility—key insights for investors.

UHS shows steady earnings growth, strategic tech adoption, and analyst “buy” ratings, making it a compelling choice for investors eyeing resilient healthcare management stocks.

Explore Bristol‑Myers Squibb’s latest market trends, analyst outlooks, and late‑stage oncology pipeline—discover why investors remain bullish on its future gains.

Merck’s share dip mirrors a market sell‑off, yet new KEYTRUDA data for ovarian cancer bolsters its oncology pipeline and investor confidence.

EssilorLuxottica faces U.S. class‑action suits over disputed tariffs, with implications for pricing, supply chains and patient costs. Learn how the legal battle could reshape eyewear affordability and industry practices.

Investors eye Siemens Healthineers: AI‑driven imaging, strong buybacks, ethical supply‑chain risks, and a spin‑off reshape the future of medical tech.